Gilead goes to Japan for Sovaldi OK; Regeneron's Eylea, Bayer's Stivargo get EU nods; Oil leaks into Teva growth hormone;

@FiercePharma: Top-read on FierceVaccines Thurs: CDC committee recommends AZ's FluMist over flu shot in children. Story | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bring out the confetti: 7 of 2013's launches will join Sovaldi, Tecfidera in blockbuster land. More | Follow @CarlyHFierce

> Gilead Sciences ($GILD) has submitted an application in Japan for approval of its wildly successful oral hepatitis C drug Sovaldi. Release

> India's Dr. Reddy's Laboratories has launched in the U.S. its generic version of Eli Lilly ($LLY) blockbuster antidepressant Cymbalta. Report

> Novartis ($NVS) is recalling 109,155 Foradil Aerolizer containing capsules of formoterol fumarate inhalation powder for treating asthma that it makes for Merck ($MRK), because they were out of specification for particle size. Report

> The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Regeneron Pharmaceuticals' ($REGN) Eylea for the treatment of sight problems related to diabetic macular edema (DME). Release

> CHMP has recommended Bayer Healthcare's cancer treatment Stivarga for the treatment of gastrointestinal stromal tumors. Story

Medical Device News

@FierceMedDev: Pharma company Merz to buy ultrasound company to strengthen beautification biz. Story | Follow @FierceMedDev

@StacyALawrence: Philips, Salesforce.com to create clinical, cloud-based platform. Story | Follow @StacyALawrence

@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. More via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Hard verdict to swallow: New York high court shoots down NYC ban on super-sized sodas. More | Follow @EmilyWFierce

> FDA clears first robotic exoskeleton for patients with spinal cord injuries. Story

> Vagus nerve stimulator effective to prevent migraines, study says. Report

> Pharma company Merz to buy ultrasound company to strengthen beautification biz. Article

Biotech News

@FierceBiotech: This week's Chutes & Ladders: Former Avila CEO Bosley signs on to lead MA's Editas. Report | Follow @FierceBiotech

@JohnCFierce: Seriously, who in their right mind would buy Eli Lilly? They don't need protection. Story | Follow @JohnCFierce

@DamianFierce: I went to BIO 2014 and talked to people about the state of partnering. Article | Follow @DamianFierce

@EmilyMFierce: WHO calls 11-nation meeting over Ebola crisis in west Africa. More | Follow @EmilyMFierce

> Shire chief hits the road, talking up an AbbVie-free future. News

> Lilly and Boehringer inch closer to challenging Lantus with EU nod. More

> Retrophin slips on liver woes in rare disease drug's first trial. Article

And Finally... The FDA says Teva Pharmaceutical Industries ($TEVA) is recalling 129,000 cartons of somatropin growth hormone which could be contaminated with silicone oil that leaked from a line during freeze drying. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.